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Background 
 
Equine viral arteritis (EVA) has become a very 
important issue in the equine industry since the 
occurrence of a disease outbreak in the Quarter 
Horse breeding industry in 2006. Equine viral 
arteritis is a contagious disease syndrome caused by 
the Equine Arteritis Virus (EAV), which can infect 
all equines. Although EVA generally causes only 
mild upper respiratory tract disease in adult horses, 
it can cause fatal pneumonia in young foals and 
abortion in pregnant mares. In addition, stallions 
infected with EAV may become persistently 
infected sub-clinically (i.e., without evidence of 
infection) and shed infectious virus in their semen 
(i.e., become virus “carriers”). Transmission of the 
virus can occur via contact with respiratory 
secretions of clinically ill animals; contact with an 
aborted fetus and its associated fetal 
membranes/fluids; and/or contact with semen from 
a chronically infected stallion. Particularly 
important is the potential for widespread 
dissemination of the virus associated with the use of 
cooled and/or frozen semen (Figure 1) from 
chronically infected stallions, which was the 
principal mode of transmission in the Quarter Horse 
industry in 2006. That outbreak has lead to 
increased recognition of the disease, and prompted 
federal and state regulatory agencies and the 
breeding industry to take a heightened approach to 
control measures for EVA. Current recommenda-
tions focus on minimizing the risk of exposure that 
would lead to the introduction of the virus into 
susceptible groups of horses; vaccination of 
susceptible, “at-risk” horses (e.g., broodmares); and 
prevention of the disease in naive stallions in order 
to avoid the persistently infected carrier state. 
 
Clinical Signs 
 
In otherwise healthy adult horses, clinical signs of 
EAV infection may not be evident. When clinical 
signs do occur, they typically become evident 3 to 7 
days post-exposure and may include: fever; 
depression; anorexia; dependent edema of the limbs 
and ventral abdomen; urticaria; supra or periorbital 
edema; conjunctivitis; lacrimal discharge and serous 
to mucoid nasal discharge. Infection in unprotected 
pregnant mares frequently leads to abortion. Young 
foals can develop severe, life-threatening 
pneumonia. 
Figure 1. Typical cooled semen transport 
containers. Photo from Equitainer. 
Diagnosis 
 
Since the clinical signs of EVA are similar to other 
causes of respiratory diseases (e.g., influenza), EVA 
should be considered in any horse showing signs of 
respiratory disease. Similarly, EVA should be 
considered in any mare that aborts her pregnancy.  
Virus isolation can be attempted from swabs of 
nose, throat or eyes; or in the case of abortion, the 
aborted fetus, fetal fluids or placenta. The most 
common method of diagnosing EVA is by 
performing serology testing of blood for EAV 
neutralizing antibodies. Although the presence of 
neutralizing antibodies does not indicate active 
infection, it does indicate exposure to EAV has 
occurred. Extremely high antibody levels in a single 
sample or a four-fold or greater rise in antibody 
level in paired samples collected 14 to 28 days apart 
are generally indicative of recent active infection. 
 
Treatment 
 
There is no specific treatment of EVA, so efforts are 
directed at supportive care, such as rest and the use 
of anti-inflammatory medication to reduce a fever.    
 
Prevention and Control 
 
First and foremost, it is important to know the EAV 
status of resident stallions and/or stallions at other 
locations that will be used for breeding purposes 
(e.g., shipped or frozen semen). Serology can be 
used to assess prior exposure of a stallion to EAV; 
however, serology cannot distinguish between 
natural infection (that may have induced a “carrier” 
state in the stallion) or prior vaccination against 
EAV. Stallions that are seronegative (titer <1:4) are 
not infective and mares can be bred to these 
stallions without risk of infection. Owners of 
seronegative stallions should strongly consider 
vaccinating the stallion to prevent the possibility of 
infection in the future with its attendant risk of 
development of the carrier state. Vaccination should 
be done at least 28 days prior to breeding/semen 
collection. Because serology cannot distinguish 
between natural infection and vaccination, it is 
imperative to have permanent documentation that a 
stallion was tested and shown to be seronegative 
prior to vaccination. 
 
Seropositive stallions (titer >1:4), that have no 
record of having been seronegative prior to 
vaccination, should have their semen tested to 
determine if they are persistently infected. Testing 
involves examining an ejaculate of semen for the 
presence of EAV by the accredited laboratory at the 
Gluck Equine Research Center at the University of 
Kentucky 
(http://www2.ca.uky.edu/gluck/serveva.asp).  
Seropositive shedding stallions must be managed 
appropriately, which involves breeding only to 
vaccinated/seropositive mares and recognizing that 
all materials that come in contact with the stallion’s 
semen are potentially infective. Vaccinated mares 
should be isolated for 21 days following their first 
breeding to a carrier stallion, because these mares 
may become transiently viremic with “wild-type” 
virus after breeding. Isolation for 21 days is not 
necessary after subsequent breeding, though 
isolation for at least 24 hours should be performed 
after every breeding to prevent mechanical spread 
of EAV if semen is voided from the mare’s 
reproductive tract. Because of the severe health risk 
of EVA in young foals, breeding post-partum mares 
(even if vaccinated) to EAV shedding stallions 
should be avoided, because of the potential for 
transmission of the virus to the mare’s foal.   
It is important to note that 
vaccinating horses against EVA 
is done using a modified-live 
virus vaccine, which can be shed 
post-vaccination (causing other 
horses to seroconvert); therefore, 
horses should be isolated for at 
least 21 days after administration 
of the vaccine.   
Many states have adopted 
statutory language governing the 
prevention and control of EVA. 
For example, the State of Utah 
requires all stallions used for 
breeding entering Utah be tested 
for Equine Viral Arteritis by an 
accredited veterinarian within 30 days prior to entry 
by rule (R58-23). Exceptions to the above are 
stallions that have proof of negative EVA status 
prior to vaccination and proof of subsequent yearly 
vaccination. No EVA carrier stallion used for 
breeding purposes shall be permitted to enter Utah 
without a prior permit from the State Veterinarian.  
No semen from a carrier stallion shall be permitted 
to enter into Utah without a prior permit from the 
Figure 2. Equine Viral 
Arteritis (EVA) vaccine 
approved for use in North 
America. 
State Veterinarian. All EVA Carrier Stallions, used 
for breeding purposes, imported into Utah shall be 
taken directly to an approved facility and shall 
remain on said facility until permission from the 
State Veterinarian is obtained to move the animal to 
another approved facility. All semen from an EVA 
Carrier Stallion imported into Utah shall be shipped 
directly to an approved facility and shall remain on 
said facility until inseminated, transported to 
another approved facility and/or disposed of. 
All stallions used for breeding purposes identified 
as EVA positive shall have their semen tested by an 
accredited veterinarian at an approved laboratory 
prior to breeding. All carrier stallions used for 
breeding purposes shall be housed and maintained 
at an approved facility until permission from the 
State Veterinarian is given to move the stallion to 
another approved facility. All EVA infected semen 
shall only be collected, handled, evaluated, 
received, packaged and/or administered at an 
approved facility. 
All equids, including but not limited to stallions, 
mares and geldings, on approved facilities shall be 
vaccinated for EVA no less than 21 days before the 
start of breeding season or no less than 21 days 
before arriving at an approved facility. Mares being 
bred to a carrier stallion, or inseminated with semen 
from a carrier stallion, shall remain on the approved 
facility for a minimum of 21 days after the initial 
breeding date. Adequate biosecurity precautions 
shall be in place during the breeding season. The 
adequacy of biosecurity may be monitored 
periodically by the Utah Department of Agriculture 
and Food. 
The private veterinary practitioner immediately 
upon receiving a positive laboratory report on EVA 
shall report all EVA positive equids to the State 
Veterinarian. All EVA positive test results 
processed at a state owned laboratory shall be 
immediately reported to the State Veterinarian. The 
State Veterinarian may require testing of any 
stallion suspected of being exposed to EAV. 
Summary 
	
Equine viral arteritis is now recognized as an 
important health threat in the equine industry, 
particularly in animals used for breeding. Through 
appropriate control and prevention procedures, such 
as serological testing and vaccination, the risk of 
EVA can be minimized. An important strategy for 
controlling EVA is prevention of the persistently 
infected carrier state in stallions. Because of the 
regulatory aspect of EVA, it is imperative that horse 
owners contact their respective states’ regulatory 
authority for information regarding rules in place 
that govern the control of EVA. 
 
Additional Information 
	
The United States Department of Agriculture 
(USDA), Animal and Plant Health Inspection 
Service (APHIS), Veterinary Services (VS) has 
several information resources about EVA that are 
available online at: 
http://www.aphis.usda.gov/animal_health/animal_di
seases/eva/ 
 
The American Association of Equine Practitioners 
(AAEP) has a fact sheet on EVA that can be 
accessed online at: http://www.aaep.org/eva.htm 
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